Health Care Biotech and Pharmaceuticals


  • I'm a 'fan' of Joe's: Fred Hassan

    I think he will find his base at Valeant, says Fred Hassan, Warburg Pincus, talking about Joseph Papa, the newly appointed CEO of Valeant.

  • FDA panel rejects Sarepta drug

    CNBC's Meg Tirrell reports on an FDA advisory committee's vote to decline the sale of an experimental drug to treat Duchenne muscular dystrophy.

  • Inventor of aspirin and maker of Yasmin birth control pills says it still expects adjusted EBITDA to increase this year.

  • The outside of the Food and Drug Administration headquarters is seen in White Oak, Md., on Monday, November 9, 2015.

    Advisers to the FDA voted on Monday not to recommend approval of possibly the first drug for Duchenne muscular dystrophy, the New York Times reports.

  • Sarepta vs. the FDA

    Sarepta interim CEO Ed Kaye reacts to FDA panel's negative decision on data supporting approval of Duchenne muscular dystrophy drug.

  • VRX vs. PRGO & SRPT vs the FDA

    CNBC's Meg Tirrell looks into Valeant Pharma's appointment of Joseph Papa to CEO, as well as Sarepta's showdown with the FDA over a muscular dystrophy drug.

  • Joseph Papa, CEO of Perrigo.

    Perrigo plummeted 13 percent in the premarket Monday after issuing very weak guidance.

  • FDA votes on muscular dystrophy drug

    Sarepta Therapeutics's Eteplirsen is in front of the FDA advisory committee today for a vote on whether the drug is effective in treating Duchenne muscular dystrophy, reports CNBC's Meg Tirrell.

  • Elizabeth Holmes, founder and CEO of Theranos

    Theranos offers a reminder of the perils of investing in Silicon Valley, where it's common for founders to control a company, the NYT reports.

  • biopharmaceuticals

    Sarepta was down sharply a day after an FDA advisory committee voted against recommending the company's Duchenne muscular dystrophy drug.

  • VRX vs. PRGO for CEO

    CNBC's Meg Tirrell reports on the possibility of Perrigo CEO Joseph Papa heading over to Valeant, as well as biotech firm Interxon feeling some pressure after the release of a report calling it 'the new Theranos.'

  • Positive news for Valeant?

    Raghuram Selvaraju, H.C. Wainwright senior biotechnology analyst, talks about Valeant offering the CEO position to Perrigo's Joseph Papa.

  • NYT's Stewart: Walgreens blindsided by Theranos

    Jim Stewart, CNBC Contributor and The New York Times Columnist, talks about the struggling relationship between Walgreens and Theranos.

  • Joseph Papa, CEO of Perrigo.

    Drugmaker Valeant Pharmaceuticals is seeking to appoint Perrigo boss Joseph Papa as its new chief executive, a source familiar with the matter said.

  • Traders work on the floor of the New York Stock Exchange underneath a board showing the name of Valeant Pharmaceuticals shortly before the opening of the markets in New York October 22, 2015.

    Pharma company Valeant has been under fire recently, but this investor says it's a buy.

  • A customer shops inside a Walgreens

    Walgreen agreed to remove stale shelf tags within 36 hours and end the use of "last chance" or "clearance" tags to promote items that are neither.

  • Shares of Sarepta Therapeutics plunge after the FDA maintains its "negative" outlook on the company's drug for a rare muscle-wasting disorder.

  • Very optimistic on Actelion’s future: CEO

    Actelion CEO Jean-Paul Clozel discusses its latest drug developments and why 2016’s first quarter was “key” for the company.

  • Actelion never made offer for ZS Pharma: CEO

    Actelion CEO, Jean-Paul Clozel talks about the changing face of the M&A space for pharmaceuticals and biotech and clearing the air on what really happened with ZS Pharma.

  • Founder & CEO of Theranos Elizabeth Holmes.

    Dick Kovacevich defended the embattled lab testing start-up's boss, Elizabeth Holmes, saying her treatment recently has been unfair.

Contact Biotech and Pharma


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    Get these newsletters delivered to your inbox, and more info about about our products and service. Privacy Policy.


  • Dan Mangan is a reporter covering health care for

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.